Celgene asserts its REVLIMID® patents against Apotex Inc. under Hatch-Waxman Act
Client(s) Celgene Corporation
Jones Day is representing Celgene Corporation as a plaintiff to enforce its patents against Apotex Inc. in a Hatch-Waxman litigation matter involving Apotex’s proposed generic versions of REVLIMID®, which is prescribed for treating multiple myeloma and other cancers.
Celgene Corporation v. Apotex Inc., No. 2-18-cv-00461 (D.N.J.)